Spyre Therapeutics, Inc.
SYRE
$14.50
$0.372.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -40.94% | -61.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | -40.94% | -61.96% |
| Cost of Revenue | 102.12% | 324.49% | 197.40% | 114.84% | 66.99% |
| Gross Profit | -103.97% | -341.08% | -206.82% | -118.19% | -72.33% |
| SG&A Expenses | 32.87% | 92.76% | 97.30% | 68.73% | 20.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.01% | 116.56% | 128.25% | 83.37% | 36.03% |
| Operating Income | -77.33% | -119.13% | -132.01% | -85.20% | -38.72% |
| Income Before Tax | 38.62% | 27.03% | 31.83% | -366.91% | -303.46% |
| Income Tax Expenses | 296.15% | 316.67% | 117.50% | 121.21% | 83.95% |
| Earnings from Continuing Operations | 38.60% | 27.01% | 31.76% | -368.15% | -304.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.60% | 27.01% | 31.76% | -368.15% | -304.21% |
| EBIT | -77.33% | -119.13% | -132.01% | -85.20% | -38.72% |
| EBITDA | -77.83% | -121.31% | -136.36% | -88.19% | -40.44% |
| EPS Basic | 94.32% | 110.75% | 100.25% | -159.96% | -130.22% |
| Normalized Basic EPS | 89.36% | 82.13% | 44.83% | -76.59% | -61.10% |
| EPS Diluted | 94.32% | 110.75% | 100.25% | -159.96% | -130.22% |
| Normalized Diluted EPS | 89.36% | 82.13% | 44.83% | -76.59% | -61.10% |
| Average Basic Shares Outstanding | 583.68% | 844.58% | 570.30% | 311.38% | 103.48% |
| Average Diluted Shares Outstanding | 583.68% | 844.58% | 570.30% | 311.38% | 103.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |